Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2016 Feb 7

PMID 26851223

Citations 11

Authors

Tatiana M Garcia-Bates

Eun Kim

Fernando Concha-Benavente

Sumita Trivedi

Robbie B Mailliard

Andrea Gambotto

Robert L Ferris

Affiliations

Soon will be listed here.

Abstract

The incidence of human papillomavirus (HPV)-related head and neck squamous cell carcinoma has increased in recent decades, though HPV prevention vaccines may reduce this rise in the future. HPV-related cancers express the viral oncoproteins E6 and E7. The latter inactivates the tumor suppressor protein retinoblastoma (Rb), which leads to the overexpression of p16(INK4) protein, providing unique Ags for therapeutic HPV-specific cancer vaccination. We developed potential adenoviral vaccines that express a fusion protein of HPV-16 E6 and E7 (Ad.E6E7) alone or fused with p16 (Ad.E6E7p16) and also encoding an anti-programmed death (PD)-1 Ab. Human monocyte-derived dendritic cells (DC) transduced with Ad.E6E7 or Ad.E6E7p16 with or without Ad.αPD1 were used to activate autologous CD8 CTL in vitro. CTL responses were tested against naturally HPV-infected head and neck squamous cell carcinoma cells using IFN-γ ELISPOT and [(51)Cr]release assay. Surprisingly, stimulation and antitumor activity of CTL were increased after incubation with Ad.E6E7p16-transduced DC (DC.E6E7p16) compared with Ad.E6E7 (DC.E6E7), a result that may be due to an effect of p16 on cyclin-dependent kinase 4 levels and IL-12 secretion by DC. Moreover, the beneficial effect was most prominent when anti-PD-1 was introduced during the second round of stimulation (after initial priming). These data suggest that careful sequencing of Ad.E6E7.p16 with Ad.αPD1 could improve antitumor immunity against HPV-related tumors and that p16 may enhance the immunogenicity of DC, through cyclin-dependent pathways, Th1 cytokine secretion, and by adding a nonviral Ag highly overexpressed in HPV-induced cancers.

Citing Articles

Viral Vector-Based Gene Therapy.

Li X, Le Y, Zhang Z, Nian X, Liu B, Yang X Int J Mol Sci. 2023; 24(9).

PMID: 37175441 PMC: 10177981. DOI: 10.3390/ijms24097736.

Evaluation of p16 in Epithelial Ovarian Cancer for a 10-Year Study in Northeast China: Significance of HPV in Correlation with PD-L1 Expression.

Yang X, You Q, Yao G, Geng J, Ma R, Meng H Cancer Manag Res. 2020; 12:6747-6753.

PMID: 32848457 PMC: 7425106. DOI: 10.2147/CMAR.S262678.

Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses.

Santos P, Adamik J, Howes T, Du S, Vujanovic L, Warren S J Exp Med. 2020; 217(7).

PMID: 32369107 PMC: 7336310. DOI: 10.1084/jem.20191369.

T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy.

Macatangay B, Gandhi R, Jones R, McMahon D, Lalama C, Bosch R AIDS. 2019; 34(1):15-24.

PMID: 31634201 PMC: 7313719. DOI: 10.1097/QAD.0000000000002406.

Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System.

Zhou C, Tuong Z, Frazer I Front Oncol. 2019; 9:682.

PMID: 31428574 PMC: 6688195. DOI: 10.3389/fonc.2019.00682.

References

Roman L, Wilczynski S, Muderspach L, Burnett A, OMeara A, Brinkman J . A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol. 2007; 106(3):558-66. DOI: 10.1016/j.ygyno.2007.05.038. View

Figdor C, de Vries I, Lesterhuis W, Melief C . Dendritic cell immunotherapy: mapping the way. Nat Med. 2004; 10(5):475-80. DOI: 10.1038/nm1039. View

Lin C, Grandis J, Carey T, Gollin S, Whiteside T, Koch W . Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck. 2007; 29(2):163-88. DOI: 10.1002/hed.20478. View

Chaturvedi A, Engels E, Pfeiffer R, Hernandez B, Xiao W, Kim E . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29(32):4294-301. PMC: 3221528. DOI: 10.1200/JCO.2011.36.4596. View

Li J, Jie H, Lei Y, Gildener-Leapman N, Trivedi S, Green T . PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2014; 75(3):508-518. PMC: 4315704. DOI: 10.1158/0008-5472.CAN-14-1215. View

Pauken K, Wherry E . Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015; 36(4):265-76. PMC: 4393798. DOI: 10.1016/j.it.2015.02.008. View

Klussmann J, Gultekin E, Weissenborn S, Wieland U, Dries V, Dienes H . Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol. 2003; 162(3):747-53. PMC: 1868106. DOI: 10.1016/S0002-9440(10)63871-0. View

Dong H, Strome S, Salomao D, Tamura H, Hirano F, Flies D . Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002; 8(8):793-800. DOI: 10.1038/nm730. View

Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C . Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res. 2005; 65(23):11146-55. DOI: 10.1158/0008-5472.CAN-05-0772. View

10.

Wieking B, Vermeer D, Spanos W, Lee K, Vermeer P, Lee W . A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther. 2012; 19(10):667-74. PMC: 3571619. DOI: 10.1038/cgt.2012.55. View

11.

Schmerling R . Toxicity of checkpoint inhibitors. Chin Clin Oncol. 2015; 3(3):31. DOI: 10.3978/j.issn.2304-3865.2014.08.03. View

12.

Gao W, Rzewski A, Sun H, Robbins P, Gambotto A . UpGene: Application of a web-based DNA codon optimization algorithm. Biotechnol Prog. 2004; 20(2):443-8. DOI: 10.1021/bp0300467. View

13.

Einstein M, Kadish A, Burk R, Kim M, Wadler S, Streicher H . Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol. 2007; 106(3):453-60. PMC: 2013935. DOI: 10.1016/j.ygyno.2007.04.038. View

14.

Ascierto P, Simeone E, Sznol M, Fu Y, Melero I . Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol. 2010; 37(5):508-16. DOI: 10.1053/j.seminoncol.2010.09.008. View

15.

Patel D, Huang S, Baglia L, McCance D . The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 1999; 18(18):5061-72. PMC: 1171577. DOI: 10.1093/emboj/18.18.5061. View

16.

Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren L, Joneberg J . Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer. 2006; 119(11):2620-3. DOI: 10.1002/ijc.22177. View

17.

Demers G, Espling E, Harry J, Etscheid B, Galloway D . Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J Virol. 1996; 70(10):6862-9. PMC: 190734. DOI: 10.1128/JVI.70.10.6862-6869.1996. View

18.

Sturgis E, Ang K . The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms?. J Natl Compr Canc Netw. 2011; 9(6):665-73. DOI: 10.6004/jnccn.2011.0055. View

19.

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N . Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002; 99(19):12293-7. PMC: 129438. DOI: 10.1073/pnas.192461099. View

20.

Doorbar J . Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006; 110(5):525-41. DOI: 10.1042/CS20050369. View